Pasireotide - CAS 396091-73-9
Catalog number: B0084-465329
Category: Inhibitor
Please be kindly noted products are not for therapeutic use. We do not sell to patients.
Molecular Formula:
C58H66N10O9
Molecular Weight:
1047.227
COA:
Inquire
Targets:
Somatostatin Receptor
Description:
Pasireotide pamoate, also known as SOM230, is an orphan drug approved for the treatment of Cushing's disease in patients who fail or are ineligible for surgical therapy. It was developed by Novartis. Pasireotide is a somatostatin analog with a 40-fold increased affinity to somatostatin receptor 5 compared to other somatostatin analogs.
Ordering Information
Catalog Number Size Price Stock Quantity
B0084-465329 5 mg $598 In stock
Bulk Inquiry
Purity:
>98%
Synonyms:
Pasireotide; SOM230; SOM-203; SOM 203; Signifor
MSDS:
Inquire
Current Developer:
Novartis
1.Serial follow-up of presurgical treatment using pasireotide long-acting release with or without octreotide long-acting release for naïve active acromegaly.
Chang JS1, Tseng HM2, Chang TC3. J Formos Med Assoc. 2016 Apr 22. pii: S0929-6646(16)30001-8. doi: 10.1016/j.jfma.2016.02.003. [Epub ahead of print]
The aim of the present study was to evaluate the serial changes of GH and IGF-1 in seven patients with naïve, active acromegaly following presurgical treatment of the somatostatin analog pasireotide long-acting release (LAR) and octreotide LAR. The patients were treated with pasireotide LAR with or without octreotide LAR for two years and underwent transsphenoidal adenomectomy. After treatment with the somatostatin analogs, the surgical cure rate was similar to that in patients who underwent transsphenoidal surgery alone. Diabetes insipidus was not identified in any patients after the operation. Pasireotide LAR was effective on GH as well as IGF-1 suppression and tumor size decreasing when used as the primary therapy. Future large-population studies to investigate the surgical curative rate after presurgical treatment with somatostatin analogs in patients with acromegaly and macroadenomas close to the cavernous sinus are warranted. However, that hyperglycemia developed following pre-surgical treatment with pasireotide should take into consideration.
2.A Single-Center 10-Year Experience with Pasireotide in Cushing's Disease: Patients' Characteristics and Outcome.
Trementino L1, Michetti G1, Angeletti A1, Marcelli G1, Concettoni C1, Cardinaletti C1, Polenta B1, Boscaro M2, Arnaldi G1. Horm Metab Res. 2016 May;48(5):290-8. doi: 10.1055/s-0042-101347. Epub 2016 Apr 29.
Pasireotide is the first pituitary-directed drug approved for treating patients with Cushing's disease (CD). Our 10-year experience with pasireotide in CD is reported here. Twenty patients with de novo, persistent, or recurrent CD after pituitary surgery were treated with pasireotide from December 2003 to December 2014. Twelve patients were treated with pasireotide in randomized trials and 8 patients with pasireotide sc (Signifor(®); Novartis AG, Basel, Switzerland) in clinical practice. The mean treatment duration was 20.5 months (median 9 months; range, 3-72 months). Urinary free cortisol (UFC) levels mean percentage change (± SD) at last follow-up was-40.4% (± 35.1; range, 2-92%; median reduction 33.3%) with a normalization rate of 50% (10/20). Ten patients achieved sustained normalized late night salivary cortisol (LNSC) levels during treatment. LNSC normalization was associated with UFC normalization in 7/10 patients. Serum cortisol and plasma ACTH significantly decreased from baseline to last follow-up.
3.Switching patients with acromegaly from octreotide to pasireotide improves biochemical control: crossover extension to a randomized, double-blind, Phase III study.
Bronstein MD1, Fleseriu M2, Neggers S3, Colao A4, Sheppard M5, Gu F6, Shen CC7,8,9, Gadelha M10, Farrall AJ11, Hermosillo Reséndiz K12, Ruffin M13, Chen Y12, Freda P14; Pasireotide C2305 Study Group. BMC Endocr Disord. 2016 Apr 2;16(1):16. doi: 10.1186/s12902-016-0096-8.
BACKGROUND: Many patients with acromegaly do not achieve biochemical control with first-generation somatostatin analogues. A large, multicenter, randomized, Phase III core study demonstrated that pasireotide LAR had significantly superior efficacy over octreotide LAR. This analysis explores the efficacy and safety of switching therapeutic arms in inadequately controlled patients during a 12-month crossover extension.
Molecular Weight Calculator Molarity Calculator Solution Dilution Calculator

Related Somatostatin Receptor Products


CAS 193829-96-8 Cortistatin 14

Cortistatin 14
(CAS: 193829-96-8)

Cortistatin 14 is an endogenous neuropeptide similar to somatostatin-14 in structure and function. It is mainly expressed in the cortex and hippocampus. It show...

CAS 133920-70-4 FK 960

FK 960
(CAS: 133920-70-4)

FK 960 is a somatostatin receptor agonist and a 5-HT agonist activating both serotonin and somatostatin production as a cognitive enhancer. The phase II clinica...

Pasireotide L-aspartate salt
(CAS: 396091-77-3)

Pasireotide is a synthetic long-acting cyclic hexapeptide exhibits unique high-affinity binding to human somatostatin receptors.

CAS 51110-01-1 Somatostatin

Somatostatin
(CAS: 51110-01-1)

Somatostatin is an endogenous peptide that inhibits the release of growth hormone, insulin and glucagon. Somatostatin also blocks voltage-dependent calcium chan...

CAS 217480-26-7 L-803,087 trifluoroacetate

L-803,087 trifluoroacetate
(CAS: 217480-26-7)

L-803,087 trifluoroacetate is the trifluoroacetate salt of L-803,087, which is a selective and potent somatostatin sst4 receptor agonist often overexpressed in ...

CAS 217480-27-8 L-817,818

L-817,818
(CAS: 217480-27-8)

L-817,818 is a selective and potent somatostatin sst5 receptor agonist with Ki value of 0.4 nM for cloned human sst5 receptors. It inhibits insulin release from...

CAS 208706-12-1 (1R,1'S,3'R/1R,1'R,3'S)-L-054,264

(1R,1'S,3'R/1R,1'R,3'S)-L-054,264
(CAS: 208706-12-1)

(1R,1'S,3'R/1R,1'R,3'S)-L-054,264 is a selective and potent somatostatin sst2 receptor agonist with Ki value of 4nm. Its Ki values are 537, 3614, 2480 and 5017 ...

CAS 79517-01-4 Octreotide acetate

Octreotide acetate
(CAS: 79517-01-4)

Octreotide acetate is a long-acting octapeptide with pharmacologic actions similars to the natural hormone somatostatin. It is a more potent inhibitor of growth...

Chemical Structure

CAS 396091-73-9 Pasireotide

Quick Inquiry

Verification code

Featured Items